Clinical trial
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic…
NCT00417209 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00417209 |
|---|---|
| Title | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen |
| Official title | A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen |
| Acronym | PAPRIKA |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | Larotaxel (XRP9881), 5-Fluorouracil, Capecitabine |
| Enrollment | 408 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Dec 29, 2006 |
| Last update posted | Jun 3, 2016 |
| Countries | Belgium, Brazil, Canada, Chile, Colombia, Czechia, Finland, Germany, Hungary, India, Italy, Mexico and 9 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: